Navigation Links
Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
Date:1/4/2008

ALLEGAN, Mich., Jan. 4 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 26th Annual JPMorgan Healthcare Conference on Wednesday, January 9, at 3:30 p.m. (PT) at the Westin St. Francis Hotel in San Francisco.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
2. Perrigo Company to Host Analyst Meeting on September 18, 2007
3. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
4. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
5. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
6. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 2007
7. Perrigo Company Announces Dividend Increase
8. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
9. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
10. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
11. Cleveland-based Health Care Tech Company Within3 Names New CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... Plano, Texas (PRWEB) , ... May 26, 2017 , ... ... Cord Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita ... , “We are pleased to be the first in Arkansas to introduce the ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: ... FAMILY-Our Journey to the Cross” is the creation of published authors, Bob and Margaret Massey. ... used to say, he is "panther quick and leather tough." His love for others ...
(Date:5/26/2017)... ... ... Water damage to the flooring of several classrooms at The Fort Lee Elementary ... number of critical issues to address before students could return to classes. , First, ... no disruption to class schedules. Second, the project had to comply with New Jersey ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a privately-held ... and developing novel compounds to treat Parkinson,s disease (PD), has ... is a Phase 1/2a randomized, controlled, multicenter study involving patients ... will enroll 50 patients over a 9-to-12-month period. The first ... 10 patients with PD. Participating sites include Denver ...
Breaking Medicine Technology: